Inpatient ophthalmology care represents a specialized and increasingly vital component of modern hospital systems, addressing complex eye conditions that require round-the-clock clinical supervision. Among the most pressing conditions managed within this setting is glaucoma — a progressive optic nerve disease that the World Health Organization identifies as the second leading cause of irreversible blindness worldwide, affecting an estimated 76 million people globally. The NIH projects this number will exceed 111 million by 2040.
This article explores two interconnected themes: evidence-based hospital protocols guiding inpatient glaucoma management, and the scientifically documented effects of tetrahydrocannabinol (THC) on intraocular pressure (IOP). Unlike routine outpatient visits, hospital-based glaucoma care involves multidisciplinary coordination, acute intervention, and continuous monitoring. Understanding these protocols matters deeply for clinicians, hospital administrators, and informed patients navigating a complex healthcare landscape where innovation and patient safety must remain equally prioritized.
Understanding Glaucoma in the Inpatient Setting: Clinical Landscape and Patient Profile
Glaucoma is not a single disease but a family of conditions united by one dangerous outcome: progressive damage to the optic nerve, often driven by elevated intraocular pressure (IOP). In the inpatient setting, three subtypes demand the most clinical attention. Acute angle-closure glaucoma (AACG) occurs when the drainage angle of the eye suddenly becomes blocked, causing IOP to spike dramatically within hours. Neovascular glaucoma develops when abnormal blood vessels grow over the eye’s drainage structures, commonly as a complication of diabetic retinopathy or retinal vein occlusion. Secondary glaucoma can follow systemic illnesses, prolonged corticosteroid use, or ocular surgery, making hospitalized patients particularly vulnerable.
Globally, glaucoma affects over 80 million people, according to Tham et al. (Ophthalmology, 2014), with AACG representing a true ocular emergency requiring immediate hospital intervention to prevent permanent vision loss. Hospitalized patients frequently carry comorbidities — hypertension, diabetes, and cardiovascular disease — that both trigger glaucoma crises and complicate their treatment.
Common Inpatient Glaucoma Presentations and Their Triggering Conditions
The following table outlines the most common inpatient glaucoma presentations alongside their primary triggering conditions.
| Presentation | Primary Trigger |
|---|---|
| Post-surgical IOP spike | Intraocular surgery, retained viscoelastic |
| Acute angle-closure crisis | Pupillary dilation, anatomical predisposition |
| Steroid-induced glaucoma | Prolonged systemic or topical corticosteroid therapy |
| Traumatic glaucoma | Blunt ocular trauma, hyphema, angle recession |
| Neovascular glaucoma | Diabetic retinopathy, central retinal vein occlusion |
Understanding this clinical landscape helps hospital teams recognize glaucoma emergencies early and deploy appropriate, timely interventions.
Hospital Protocols for Acute Glaucoma Management: Standards of Care
When a patient arrives at the emergency department with acute angle-closure glaucoma (AACG), every minute matters. Elevated intraocular pressure (IOP) can permanently damage the optic nerve within hours, making rapid, evidence-based intervention an absolute clinical priority. Hospitals following American Academy of Ophthalmology (AAO) Preferred Practice Patterns deploy a structured, stepwise approach to reverse the crisis and protect long-term vision.
Treatment begins immediately with a combination of topical and systemic medications targeting IOP reduction through different mechanisms:
| Medication | Class | Primary Action |
|---|---|---|
| Timolol (0.5%) | Beta-blocker | Reduces aqueous humor production |
| Brimonidine (0.2%) | Alpha-agonist | Decreases aqueous production; increases outflow |
| Dorzolamide | Carbonic anhydrase inhibitor | Suppresses aqueous secretion |
| Acetazolamide (500 mg IV/oral) | Systemic CAI | Rapid systemic aqueous suppression |
| Mannitol (1–2 g/kg IV) | Hyperosmotic agent | Draws fluid from vitreous; rapidly lowers IOP |
This multi-agent approach exploits complementary pathways, achieving faster pressure reduction than any single drug alone.
Acute Angle-Closure Glaucoma Management
During an acute episode, IOP must be measured every 30 to 60 minutes until the pressure stabilizes below 35 mmHg and symptoms resolve. Continuous monitoring allows clinicians to assess medication response and escalate treatment promptly when needed.
Once IOP is medically controlled, laser peripheral iridotomy (LPI) serves as the gold-standard definitive treatment. LPI creates a small opening in the peripheral iris, restoring normal aqueous flow and permanently relieving the anatomical blockage responsible for angle closure.
Effective AACG management also requires seamless collaboration across departments. Ophthalmology leads clinical decision-making, emergency medicine manages initial stabilization, internal medicine monitors systemic comorbidities, and anesthesiology supports procedural safety when necessary.
Inpatient Acute Angle-Closure Glaucoma Management Protocol
The following seven-step protocol outlines the structured approach hospitals use to manage acute angle-closure glaucoma from initial assessment through discharge planning.
- Assessment – Confirm diagnosis via slit-lamp examination and gonioscopy
- IOP Measurement – Establish baseline pressure using tonometry
- Pharmacological Reduction – Initiate combined topical and systemic agents immediately
- Surgical Planning – Schedule LPI once IOP reaches a safe threshold
- Post-Procedure Monitoring – Recheck IOP at 1 hour, 24 hours, and one week
- Patient Education – Explain the condition, treatment rationale, and warning signs
- Discharge Planning – Arrange follow-up ophthalmology appointments and prescribe maintenance therapy
Adherence to this stepwise protocol ensures consistent, evidence-based care that minimizes the risk of permanent vision loss in acute glaucoma emergencies.
IOP Monitoring Technology in Hospital Settings: Advancing Accuracy and Safety
Accurate intraocular pressure (IOP) measurement is fundamental to glaucoma management, and hospital settings demand technologies that balance precision with practical adaptability.
- Goldmann applanation tonometry (GAT) remains the gold standard, offering reliable measurements by calculating the force needed to flatten a small corneal area. However, GAT requires a slit lamp and patient cooperation, limiting its use in bedridden individuals.
- Non-contact tonometry uses an air puff to estimate IOP without touching the eye, offering quick screening but reduced accuracy in critically ill patients.
- Rebound tonometry (iCare) has gained significant traction in inpatient settings due to its portability and ability to measure IOP without anesthesia, making it ideal for sedated or uncooperative patients.
- Pneumotonometry offers another alternative, particularly useful when corneal irregularities affect other methods.
Measuring IOP in bedridden or sedated patients presents genuine clinical challenges, as body position significantly influences readings. Clinicians must account for postural variations when interpreting results.
Emerging continuous IOP monitoring technologies, such as the SENSIMED Triggerfish contact lens sensor, represent a promising frontier by capturing 24-hour IOP fluctuation patterns — critical data often missed by single-point measurements.
Integration with electronic health records (EHR) enables real-time IOP trend tracking, supporting faster clinical decisions and interdisciplinary communication.
Patient safety surveillance is especially critical in ICU patients receiving corticosteroids or undergoing mechanical ventilation, both of which can elevate IOP significantly without obvious symptoms.
Comparison of IOP Monitoring Devices for Inpatient Use
The following table compares the key IOP monitoring devices available for inpatient use across dimensions of portability, accuracy, patient suitability, and clinical setting compatibility.
| Device | Portability | Accuracy | Patient Suitability | Clinical Setting Compatibility |
|---|---|---|---|---|
| Goldmann Applanation Tonometry (GAT) | Low — requires slit lamp setup | Highest (gold standard) | Cooperative, ambulatory patients only | Outpatient clinics; limited inpatient use |
| Non-Contact Tonometry (NCT) | Moderate — tabletop device | Moderate; affected by corneal conditions | Cooperative patients; not suitable for sedated individuals | Screening settings; limited ICU utility |
| Rebound Tonometry (iCare) | High — handheld device | Good; validated for bedside use | Excellent for bedridden, pediatric, or sedated patients | Strong inpatient and ICU compatibility |
| Pneumotonometry | Moderate — portable versions available | Good; useful with irregular corneas | Suitable for patients with corneal pathology | Inpatient wards and specialty units |
| SENSIMED Triggerfish (Contact Lens Sensor) | High — wearable technology | Captures continuous 24-hour fluctuations | Suitable for cooperative patients; emerging inpatient use | ICU monitoring and glaucoma surveillance wards |
Selecting the appropriate tonometry device based on patient condition and clinical setting is essential to ensuring accurate IOP data and safe, timely glaucoma management in hospital environments.
Multidisciplinary and Patient-Centered Approaches to Inpatient Glaucoma Care
Effective inpatient glaucoma management extends well beyond the ophthalmology ward. It depends on a carefully coordinated network of specialists, trained nursing staff, and patient-centered communication strategies working together within a structured hospital system.
The Role of Ophthalmology Consultation Services
Rapid-response ophthalmology teams are activated when acute intraocular pressure (IOP) elevation is suspected. These teams integrate seamlessly with neurology — particularly in cases where intracranial pressure (ICP) elevation mimics or compounds glaucomatous damage — and with endocrinology when steroid-induced glaucoma requires medication adjustment. Nephrology involvement becomes critical when hyperosmotic agents like mannitol are considered for patients with compromised renal function, as dosing errors can cause serious systemic harm.
Nursing Protocols and Staff Readiness
Nursing staff serve as the frontline of inpatient glaucoma monitoring. Comprehensive training programs focus on three core competencies:
- Accurate IOP measurement using tonometry devices
- Precise medication administration timing (particularly for pressure-lowering drops and IV agents)
- Early recognition of acute angle-closure symptoms including sudden eye pain, nausea, and vision blurring
These skills support timely intervention, safe treatment, and effective monitoring of patients at risk of glaucoma-related complications.
Patient-Centered Care Principles
Acute angle-closure glaucoma is a painful, frightening experience. Pain management protocols must be initiated promptly, alongside counseling to address vision-loss anxiety. Informed consent processes for inpatient surgical interventions — such as laser iridotomy — must be conducted clearly, using health literacy tools like visual diagrams, simplified language handouts, and interpreter services where needed. The Joint Commission mandates effective patient communication and safety standards in ophthalmology settings, ensuring patients fully understand their diagnosis, treatment trajectory, and discharge plan before leaving the hospital.
Inpatient Glaucoma Patient Care Checklist for Nursing Staff
The following checklist outlines the key observation points, monitoring frequencies, and escalation criteria that nursing staff must follow when caring for inpatient glaucoma patients.
| Observation Point | Frequency | Escalation Criteria |
|---|---|---|
| IOP measurement | Every 4–6 hours | IOP > 30 mmHg → notify ophthalmologist immediately |
| Topical drop administration | Per prescribed schedule | Missed dose → document and report |
| Pain assessment (eye/head) | Every shift | Severe or worsening pain → urgent review |
| Visual acuity monitoring | Once daily or as ordered | Sudden vision change → emergency consultation |
| Nausea/vomiting assessment | Every shift | May indicate acute IOP spike |
| Medication side-effect check | Every shift | Bradycardia (beta-blockers), electrolyte imbalance (CAIs) |
| Patient understanding of condition | At admission and discharge | Low literacy → activate health education tools |
Consistent adherence to this nursing checklist supports early detection of complications and ensures that inpatient glaucoma patients receive safe, coordinated, and timely care throughout their hospital stay.
Surgical Glaucoma Interventions in the Hospital: From Emergency Procedures to Planned Surgery
Inpatient glaucoma surgery spans a wide clinical spectrum, from urgent procedures performed within hours of admission to carefully scheduled elective operations. Laser peripheral iridotomy (LPI) addresses acute angle-closure by creating a small drainage opening in the iris. Trabeculectomy remains the gold-standard filtration surgery, creating a controlled fluid outlet beneath the conjunctiva. Glaucoma drainage devices (GDDs) — including Ahmed and Baerveldt valves — redirect aqueous humor through implanted tubes when trabeculectomy is unsuitable. Cyclophotocoagulation uses laser energy to reduce aqueous production, typically reserved for refractory cases.
Emergency indications include acute angle-closure crisis with IOP exceeding 40 mmHg, corneal decompensation, or medication-refractory pressure spikes. Elective indications involve progressive optic nerve damage despite maximum tolerated medical therapy.
Pre-operative hospital protocols require thorough systemic workup: cardiac clearance, blood pressure optimization, and complete medication reconciliation. Anticoagulants are typically paused according to standardized bridging protocols. Systemic IOP-lowering agents like acetazolamide may be continued or adjusted based on surgical timing.
Post-operative inpatient care focuses on IOP surveillance, wound integrity assessment, infection monitoring, and a carefully structured steroid taper to prevent both inflammation and surgical bleb failure. Nursing staff conduct hourly IOP checks during the immediate post-operative period.
Hospital efficiency considerations include strategic operating room scheduling, instrument sterilization turnaround, and clear same-day discharge criteria. Patients meeting stable IOP, adequate pain control, and reliable follow-up conditions may be discharged within 24 hours.
Surgical Procedures: Indications, Outcomes, and Hospital Stay
The following table summarizes the key surgical procedures used in inpatient glaucoma management, including their indications, expected IOP reduction, typical hospital stay, and post-operative monitoring priorities.
| Procedure | Indication | Typical IOP Reduction | Hospital Stay | Key Post-Op Monitoring |
|---|---|---|---|---|
| LPI | Acute angle-closure | 30–50% | Same-day | IOP, corneal clarity |
| Trabeculectomy | Progressive open-angle glaucoma | 40–60% | 1–2 days | Bleb integrity, IOP, infection |
| Ahmed/Baerveldt GDD | Refractory/secondary glaucoma | 30–50% | 2–3 days | Tube position, IOP, inflammation |
| Cyclophotocoagulation | End-stage/refractory glaucoma | 25–45% | Same-day to 1 day | IOP, pain, inflammation |
Trabeculectomy achieves long-term success rates of approximately 70–85% at five years, while GDDs carry measurable complication profiles including tube erosion and hypotony, representing critical benchmarks for hospital quality reporting.
THC and Intraocular Pressure: Mechanisms, Evidence, and Clinical Relevance
Delta-9-tetrahydrocannabinol (THC), the primary psychoactive compound in cannabis, interacts with the body’s endocannabinoid system (ECS) — a signaling network that regulates numerous physiological functions. Within ocular tissue, CB1 receptors are expressed in the ciliary body, trabecular meshwork, and retina. When THC binds to these CB1 receptors, it triggers a cascade that reduces aqueous humor production and may enhance uveoscleral outflow, both mechanisms that lower intraocular pressure (IOP).
The foundational research dates to 1971, when Hepler and Frank published landmark findings in JAMA demonstrating that smoked cannabis reduced IOP by approximately 25–30% in healthy subjects. Subsequent studies throughout the 1970s and 1980s confirmed measurable IOP reductions, generating significant scientific and public interest in cannabis as a potential glaucoma therapy.
However, the critical clinical limitation is duration. THC’s IOP-lowering effect persists for only 3–4 hours, meaning effective pressure control would require dosing 6–8 times daily — a frequency that is both impractical and medically problematic. Additionally, THC carries significant systemic risks: tachycardia, blood pressure fluctuation, CNS sedation, and psychoactive effects that are especially concerning for inpatient and perioperative settings where patient stability is paramount.
Based on this evidence, the American Academy of Ophthalmology (AAO) does not recommend cannabis for glaucoma management, citing insufficient sustained efficacy and an unacceptable side-effect profile relative to established therapies.
Key Studies on THC and IOP Reduction
The following table summarizes the key clinical studies examining the effects of THC on intraocular pressure, including their methods, findings, and identified limitations.
| Author(s) | Year | Method | IOP Reduction | Duration of Effect | Clinical Limitations |
|---|---|---|---|---|---|
| Hepler & Frank | 1971 | Smoked cannabis, healthy subjects | ~25–30% | 3–4 hours | Short duration; psychoactive effects |
| Merritt et al. | 1980 | Smoked cannabis, glaucoma patients | ~25% | 3–4 hours | Cardiovascular side effects; tachycardia noted |
| Flom et al. | 1975 | Oral THC administration | ~16–24% | 2–3 hours | Inconsistent absorption; CNS sedation |
| Purnell & Gregg | 1975 | Topical THC formulation | Minimal effect | Short-lived | Poor ocular bioavailability |
The evidence collectively confirms that while THC demonstrably reduces IOP, its short action window and systemic risks make it unsuitable as a reliable glaucoma treatment within hospital protocols.
THC Use in Hospitalized Glaucoma Patients: Risks, Drug Interactions, and Hospital Safety Considerations
When a patient is admitted for glaucoma-related care, their full medication picture matters — and that increasingly includes cannabis. Hospitalized patients who regularly use THC represent a growing clinical reality that demands structured attention during medication reconciliation. Ignoring cannabis use can lead to dangerous oversights.
THC can interact with several standard inpatient glaucoma medications in meaningful ways, as outlined in the table below.
| Medication Class | Potential THC Interaction |
|---|---|
| Beta-blockers (e.g., timolol) | Additive blood pressure lowering; risk of hypotension |
| Alpha-agonists (e.g., brimonidine) | Enhanced CNS depression; sedation risk |
| Anesthetic agents | Altered drug metabolism; unpredictable sedation depth |
THC use within 72 hours before surgery raises specific concerns. It can alter anesthetic requirements, destabilize hemodynamic responses, and — if the patient is acutely intoxicated — complicate informed consent evaluation. Anesthesiologists need this information before any procedure begins.
Hospital Safety Protocol Checklist: Managing THC-Using Patients
The following checklist outlines the essential steps hospitals should follow when managing inpatient glaucoma patients with known or suspected THC use.
- Screen for substance use on admission using validated tools
- Document all THC use in the electronic health record (EHR)
- Notify the ophthalmologist and anesthesiology team immediately
- Conduct a full drug interaction review before prescribing
- Delay elective procedures if acute intoxication is suspected
- Reassess informed consent capacity independently
Consistent application of this checklist helps protect patient safety and supports transparent, coordinated care across all clinical teams involved in the patient’s management.
Where cannabis is legally permitted, hospitals must develop clear, non-punitive policies for managing patient-reported THC use without compromising care quality. The American Society of Anesthesiologists (2022) has issued guidance urging standardized preoperative cannabis screening, reinforcing that transparent documentation protects both patients and providers.
THC, Neuroprotection, and Future Research Directions in Glaucoma
Beyond lowering intraocular pressure, cannabinoids may offer a second layer of benefit: protecting the retinal ganglion cells themselves. Researcher Stephen Yazulla, writing in Progress in Retinal and Eye Research (2008), highlighted preclinical evidence suggesting that both THC and CBD interact with the eye’s endocannabinoid system in ways that could shield neurons from degeneration — a concept known as neuroprotection.
Animal studies have reinforced this possibility. When cannabinoid receptors were activated in rodent models under ischemic stress, retinal neurons demonstrated measurable anti-apoptotic responses, meaning fewer cells died under conditions mimicking glaucomatous damage.
However, translating these findings to humans remains an unmet challenge. No robust clinical trial has yet confirmed cannabinoid-driven neuroprotection in glaucoma patients. The gap between promising laboratory results and validated human therapy remains significant.
Researchers are actively exploring topical cannabinoid delivery systems designed to act locally on the eye, bypassing the systemic side effects of inhaled or ingested THC. Synthetic cannabinoid analogs targeting ocular receptors without psychoactive properties are also under investigation.
Should these approaches advance to Phase II or III trials, hospitals and academic medical centers — with their established clinical infrastructure, multidisciplinary teams, and ethical oversight frameworks — will be uniquely positioned to lead this emerging research frontier.
Discharge Planning, Follow-Up Protocols, and Long-Term Glaucoma Management Post-Hospitalization
Effective discharge planning is a critical bridge between inpatient glaucoma care and long-term visual preservation. Before a patient leaves the hospital, clinicians must confirm that intraocular pressure (IOP) has reached a stable, target range — typically below 21 mmHg, though individualized targets may be lower depending on disease severity.
- Stable vision measurements
- Confirmed wound integrity following surgical interventions
- Demonstrated ability to self-administer prescribed eye drop regimens correctly
Structured discharge documentation should include:
- Written medication instructions in plain language
- Confirmed follow-up appointments within one week of discharge — consistent with American Academy of Ophthalmology (AAO) recommendations
- Clearly defined escalation pathways should symptoms such as sudden vision loss, severe eye pain, or halos around lights recur
Transition-of-care communication is equally essential. Inpatient-to-outpatient handoff documentation must reach both the patient’s ophthalmologist and primary care physician, ensuring coordinated, continuous management. Medication adherence remains a significant post-discharge challenge, as glaucoma drop regimens can be complex, costly, and time-sensitive. Digital tools — including smartphone reminder applications and teleophthalmology platforms — are increasingly used to support adherence.
Telehealth plays a growing role in post-hospitalization monitoring, enabling remote IOP tracking, virtual specialist check-ins, and digital visual field assessments for patients with mobility or geographic barriers.
Glaucoma Inpatient Discharge Checklist
The following checklist provides a structured framework for confirming that all essential discharge criteria and communication steps have been completed before a glaucoma patient leaves the hospital.
| Checklist Item | Confirmed |
|---|---|
| IOP target confirmed within acceptable range | ☐ |
| Medications dispensed and administration technique verified | ☐ |
| Follow-up appointment scheduled within 1 week | ☐ |
| Red flag symptoms reviewed with patient and caregiver | ☐ |
| Transition communication sent to outpatient care team | ☐ |
Completing each item on this checklist before discharge helps ensure continuity of care and reduces the risk of preventable complications in the post-hospitalization period.
Conclusion
Effective inpatient glaucoma management demands coordinated, protocol-driven, multi-specialty hospital care firmly grounded in patient safety and current clinical evidence. Advanced monitoring technologies — from continuous IOP sensors to AI-assisted imaging — alongside surgical excellence remain central to optimizing outcomes for hospitalized glaucoma patients.
Regarding THC, evidence confirms measurable short-term intraocular pressure reduction; however, its brief duration of action, systemic side effects, and potential drug interactions disqualify it as a replacement for established hospital glaucoma protocols. That said, rigorous cannabinoid research continues to evolve and deserves serious scientific attention.
Looking ahead, the convergence of medical innovation, patient-centered care models, and emerging pharmacological discoveries will continue reshaping hospital-based ophthalmology. Institutions that embrace evidence-based protocols, invest in advanced technology, and remain open to scientifically validated new therapies will be best positioned to deliver safer, more effective glaucoma care for every patient.